New drug combo aims to control aggressive blood cancer in younger adults
NCT ID NCT02427620
Summary
This study is testing a two-part treatment approach for younger patients newly diagnosed with mantle cell lymphoma, an aggressive type of blood cancer. First, patients receive a targeted pill (ibrutinib) plus an immunotherapy drug (rituximab) to attack the cancer cells. If they respond well, they then receive a more intensive chemotherapy regimen to try to control the disease long-term.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.